Tzanakaki G, Blackwell C C, Kremastinou J, Weir D M, Mentis A, Fallon R J
National Meningitis Reference Laboratory, Hellenic Institute Pasteur, Athens, Greece.
J Med Microbiol. 1993 Jan;38(1):19-22. doi: 10.1099/00222615-38-1-19.
The increase in the number of cases of meningococcal disease reported to the Ministry of Health in Athens since 1989 prompted the present study to determine if isolates from patients or carriers expressed the same phenotypic characters as those in other parts of Europe. None of the isolates from patients (31) or carriers (547) expressed the antigenic combinations associated with outbreaks in northern Europe, i.e., B:15:P1.16 or B:4:P1.15. The majority of the Greek isolates did not react with any of the six monoclonal serotype reagents tested; however, most reacted with one or more of the 11 monoclonal subtype antibodies. The results suggest that additional serotype reagents are needed for epidemiological studies in southeastern Europe and that vaccines based on serotype antigens developed against outbreak strains in northern Europe would not be effective in Greece.
自1989年以来，雅典向卫生部报告的脑膜炎球菌病病例数有所增加，这促使本研究确定患者或携带者的分离株是否表现出与欧洲其他地区相同的表型特征。患者（31例）或携带者（547例）的分离株均未表现出与北欧疫情相关的抗原组合，即B:15:P1.16或B:4:P1.15。大多数希腊分离株与所测试的六种单克隆血清型试剂均无反应；然而，大多数与11种单克隆亚型抗体中的一种或多种发生反应。结果表明，东南欧的流行病学研究需要更多的血清型试剂，并且基于针对北欧疫情菌株开发的血清型抗原的疫苗在希腊将无效。
